JIN MEDICAL INTERNATIONAL LTD. Class A Ordinary Shares (ZJYL)

FairStock Score: 50/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as Graham would: first ask what the business earns on capital, then what I pay for it. Jin Medical designs and sells wheelchairs, oxygen concentrators, bath aids and rehabilitative devices; it is a micro-cap of $17.1M at the 2026-10-13 close of $2.06. FairStock’s numbers show P/E 10.30 and P/B 0.53. The P/B is the interesting part: the market values it at roughly half book, and FairStock’s Graham Number is $4.47, implying a 53.91% margin of safety. But cheapness alone is not enough. The quality signals are poor. ROE is 4.02% and ROCE just 0.50%, which tells me the company earns little on the capital employed. Piotroski F-Score is 2/9, Altman Z-Score is 1.39, and D/E is 0.69 — not a fortress balance sheet by these FairStock measures. I see no evidence of a durable moat; low returns on capital suggest limited pricing power in a competitive medical-products niche. Growth is also opaque: revenue growth and profit growth are N/A, and FairStock assigns no Lynch category because there are only 0 years of filed results versus the three needed. That lack of history matters. The beta of 7.33 and 52W range of $1.53-$8.48 indicate violent price swings. So this is a classic statistical cheapness versus business quality tension: the asset value may be real, but weak returns, weak financial-health scores, and no track record make it speculative. I would need several years of filed results and improving ROCE before calling it a sound value proposition.

In plain English: Jin Medical makes wheelchairs, oxygen concentrators, and living aids for people with disabilities, the elderly, and people recovering from injury. The business looks weak on profitability and financial-strength measures, even though the stock trades below the value of its assets on the books and below a conservative value estimate. The price looks cheap relative to those measures, but the company’s limited filing history and high price swings make the picture uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer